BeiGene R&D is expected to exceed 10 billion, what is the confidence?

With the disclosure of the first half of 2022 performance reports of A-share and Hong Kong-listed companies, the R&D investment of pharmaceutical companies has also surfaced

Source: Minnet

BeiGene currently has 16 new drugs that have been commercialized 3 self-developed products, but only 8 products have sales, half of the products need to burn money for research and development, follow-up listing still needs time, sales costs, which means that the current commercial realization of sales obviously can not run the R & D investment funds, but the first half of the R & D expenses are still 860 million yuan

Since its inception, BeiGene has not had any financial year that has been profitable, almost all of which have invested heavily in research and development, with huge losses

According to the data, BeiGene's product revenue in the first half of this year was 3.

Zebutinib achieved global sales of $233.

In the United States, zebutinib has been approved for three indications; In China, zebutinib has been approved for three indications, and all of them have been included in the national medical insurance directory

As the first local original research new drug to go overseas, the commercial layout of zebutinib has now covered more than 50 countries and regions around the world, including the United States, China, the European Union, the United Kingdom, Canada, Australia, South Korea and Switzerland

Another product, PD-1, has also grown well in performance, and this year's sales will surpass Cinda's PD-1

Thanks to the three new indications in China, a total of 9 indications of terelizumab have been approved, becoming the most approved anti-PD-1 monoclonal antibody

In the future, in terms of going to sea, the layout of tirelizumab is also in a leading position

In the past, in China's pharmaceutical market, generic drugs accounted for more than 70%, plus the original research drugs in the patent period, and the non-patent drug market exceeded 90%.

However, in the past four years, a series of new medical reform policies, such as the state's continuous centralized procurement, the cancellation of drug bonuses, the reform of medical insurance payment methods, and the reform of the drug review and approval system, have completely subverted the logic

For thousands of domestic pharmaceutical companies, it may be increasingly difficult to make profits from generic proprietary Chinese medicines, and R&D innovation may be the only way to

In terms of R&D investment, last year, 247 R&D investment exceeded 100 million yuan, with a total amount of more than 100 billion yuan

The increasing attention of domestic pharmaceutical companies in research and development will be the future trend, but there are still pharmaceutical companies on the sidelines, hoping for changes

As one of the most radical pharmaceutical companies in research and development, BeiGene has seen its competitiveness
in the downward environment.
In the environment of deepening collection, the hospital will pay more attention to clinical research capabilities in the future, which also happens to be the advantage of
BeiGene's commercial promotion.

In June 2021, the State Council issued the Opinions on Promoting the High-quality Development of Public Hospitals, requiring the construction of national and provincial high-level hospitals
.
Among them, "carrying out cutting-edge medical science and technology innovation research and transformation of achievements" is an important content, the purpose is to drive the national medical level "to a new level"
.

For the hospital, the development route of the former large-scale and increased income generation has become impossible
.
On the contrary, the high-quality development of scientific research output and achievement transformation is regarded as a top priority
.
Nowadays, Phase I and Phase II clinical trials are important indicators of national assessment of scientific research hospitals, and the demand for clinical research is rising
for doctors in public hospitals.

For BeiGene, its strong R&D capabilities, rich pipelines, and demanding clinical requirements declared by China and the United States just meet the scientific research standards of many hospitals, and also pave the way
for commercial promotion in its new environment.

summary

As of Sept.
8, BeiGene had a total of 70 new drugs in research, including 16 commercial products (source Insight data
).
Most of the early new drug projects (before clinical phase II) were dual antibodies, in addition, they also included ADCs, PROTACs, antibody-based fusion proteins, AND CAR-T cell therapies
.
The targets include CD3, RAF, HER2, BCMA, etc.
, including major popular target therapies
.
A deep and differentiated R&D pipeline covers 80% of the world's cancer species
.
BeiGene's current vigorous research and development can provide a glimpse into its future ambitions
.

Resources:

1.
https://baijiahao.
baidu.
com/s?id=1741426498432060023&wfr=spider&for=pc

2.
https://baijiahao.
baidu.
com/s?id=1740734098528124130&wfr=spider&for=pc

3.